Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Factors in the disease severity of ATP1A3 mutations: Impairment, misfolding, and allele competition.

Arystarkhova E, Haq IU, Luebbert T, Mochel F, Saunders-Pullman R, Bressman SB, Feschenko P, Salazar C, Cook JF, Demarest S, Brashear A, Ozelius LJ, Sweadner KJ.

Neurobiol Dis. 2019 Aug 16:104577. doi: 10.1016/j.nbd.2019.104577. [Epub ahead of print]

PMID:
31425744
2.

Inflammatory Bowel Disease and Parkinson's Disease: A Reply to Letter to the Editor of Shih-Wei Lai.

Weimers P, Halfvarson J, Saunders-Pullman R, Ludvigsson JF, Peter I, Olén O, Burisch J.

Inflamm Bowel Dis. 2019 Aug 13. pii: izz181. doi: 10.1093/ibd/izz181. [Epub ahead of print] No abstract available.

PMID:
31406980
3.

SGCE Myoclonus-Dystonia.

Raymond D, Saunders-Pullman R, Ozelius L.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2003 May 21 [updated 2019 Aug 8].

4.

Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.

Agalliu I, Ortega RA, Luciano MS, Mirelman A, Pont-Sunyer C, Brockmann K, Vilas D, Tolosa E, Berg D, Warø B, Glickman A, Raymond D, Inzelberg R, Ruiz-Martinez J, Mondragon E, Friedman E, Hassin-Baer S, Alcalay RN, Mejia-Santana H, Aasly J, Foroud T, Marder K, Giladi N, Bressman S, Saunders-Pullman R.

Mov Disord. 2019 Jul 26. doi: 10.1002/mds.27807. [Epub ahead of print]

PMID:
31348549
5.

When to Start Levodopa Therapy for Parkinson's Disease.

Bressman S, Saunders-Pullman R.

N Engl J Med. 2019 Jan 24;380(4):389-390. doi: 10.1056/NEJMe1814611. No abstract available.

PMID:
30673551
6.

Deep Brain Stimulation in Isolated Dystonia With a GNAL Mutation.

Sarva H, Trosch R, Kiss ZHT, Furtado S, Luciano MS, Glickman A, Raymond D, Ozelius LJ, Bressman SB, Saunders-Pullman R.

Mov Disord. 2019 Feb;34(2):301-303. doi: 10.1002/mds.27585. Epub 2018 Dec 10. No abstract available.

7.

DMS as an orthogonal separation to LC/ESI/MS/MS for quantifying isomeric cerebrosides in plasma and cerebrospinal fluid.

Xu H, Boucher FR, Nguyen TT, Taylor GP, Tomlinson JJ, Ortega RA, Simons B, Schlossmacher MG, Saunders-Pullman R, Shaw W, Bennett SAL.

J Lipid Res. 2019 Jan;60(1):200-211. doi: 10.1194/jlr.D089797. Epub 2018 Nov 9.

PMID:
30413651
8.

Evidence for increased completed suicide in first-degree relatives of LRRK2 G2019S mutation Parkinson's disease.

Ortega RA, Groves M, Mirelman A, Alcalay RN, Raymond D, Elango S, Mejia-Santana H, Giladi N, Marder K, Bressman SB, Saunders-Pullman R.

J Neurol Neurosurg Psychiatry. 2019 Jul;90(7):843-844. doi: 10.1136/jnnp-2018-319364. Epub 2018 Nov 8. No abstract available.

PMID:
30409888
9.

Repeated Spiral Drawings in Essential Tremor: a Possible Limb-Based Measure of Motor Learning.

Kim CY, Luo L, Yu Q, Mirallave A, Saunders-Pullman R, Lipton RB, Louis ED, Pullman SL.

Cerebellum. 2019 Apr;18(2):178-187. doi: 10.1007/s12311-018-0974-x.

PMID:
30206795
10.

Increased substantia nigra echogenicity in LRRK2 family members without mutations.

Pullman M, Ortega R, Glickman A, Deik A, Raymond D, Marder K, Giladi N, Bressman S, Hagenah J, Brüggemann N, Saunders-Pullman R.

Mov Disord. 2018 Sep;33(9):1504-1505. doi: 10.1002/mds.27443. Epub 2018 Aug 25. No abstract available.

PMID:
30145825
11.

Finding useful biomarkers for Parkinson's disease.

Chen-Plotkin AS, Albin R, Alcalay R, Babcock D, Bajaj V, Bowman D, Buko A, Cedarbaum J, Chelsky D, Cookson MR, Dawson TM, Dewey R, Foroud T, Frasier M, German D, Gwinn K, Huang X, Kopil C, Kremer T, Lasch S, Marek K, Marto JA, Merchant K, Mollenhauer B, Naito A, Potashkin J, Reimer A, Rosenthal LS, Saunders-Pullman R, Scherzer CR, Sherer T, Singleton A, Sutherland M, Thiele I, van der Brug M, Van Keuren-Jensen K, Vaillancourt D, Walt D, West A, Zhang J.

Sci Transl Med. 2018 Aug 15;10(454). pii: eaam6003. doi: 10.1126/scitranslmed.aam6003. Review.

12.

Digitized spiral analysis may be a potential biomarker for brachial dystonia.

Ratliff J, Ortega RA, Ooi HY, Mirallave A, Glickman A, Yu Q, Raymond D, Bressman S, Pullman S, Saunders-Pullman R.

Parkinsonism Relat Disord. 2018 Dec;57:16-21. doi: 10.1016/j.parkreldis.2018.07.004. Epub 2018 Jul 20.

PMID:
30037691
13.

Inflammatory Bowel Disease and Parkinson's Disease: A Nationwide Swedish Cohort Study.

Weimers P, Halfvarson J, Sachs MC, Saunders-Pullman R, Ludvigsson JF, Peter I, Burisch J, Olén O.

Inflamm Bowel Dis. 2019 Jan 1;25(1):111-123. doi: 10.1093/ibd/izy190.

PMID:
29788069
14.

Application of the Movement Disorder Society prodromal criteria in healthy G2019S-LRRK2 carriers.

Mirelman A, Saunders-Pullman R, Alcalay RN, Shustak S, Thaler A, Gurevich T, Raymond D, Mejia-Santana H, Orbe Reilly M, Ozelius L, Clark L, Gana-Weisz M, Bar-Shira A, Orr-Utreger A, Bressman SB, Marder K, Giladi N; AJ LRRK2 Consortium.

Mov Disord. 2018 Jul;33(6):966-973. doi: 10.1002/mds.27342. Epub 2018 Mar 30.

15.

Chitinase-3-like Protein 1: A Progranulin Downstream Molecule and Potential Biomarker for Gaucher Disease.

Jian J, Chen Y, Liberti R, Fu W, Hu W, Saunders-Pullman R, Pastores GM, Chen Y, Sun Y, Grabowski GA, Liu CJ.

EBioMedicine. 2018 Feb;28:251-260. doi: 10.1016/j.ebiom.2018.01.022. Epub 2018 Jan 31.

16.

Progression in the LRRK2-Asssociated Parkinson Disease Population.

Saunders-Pullman R, Mirelman A, Alcalay RN, Wang C, Ortega RA, Raymond D, Mejia-Santana H, Orbe-Reilly M, Johannes BA, Thaler A, Ozelius L, Orr-Urtreger A, Marder KS, Giladi N, Bressman SB; LRRK2 Ashkenazi Jewish Consortium.

JAMA Neurol. 2018 Mar 1;75(3):312-319. doi: 10.1001/jamaneurol.2017.4019.

17.

Sex differences in LRRK2 G2019S and idiopathic Parkinson's Disease.

San Luciano M, Wang C, Ortega RA, Giladi N, Marder K, Bressman S, Saunders-Pullman R; Michael J Fox Foundation LRRK2 Consortium.

Ann Clin Transl Neurol. 2017 Oct 19;4(11):801-810. doi: 10.1002/acn3.489. eCollection 2017 Nov.

18.

Cognitive and motor functioning in elderly glucocerebrosidase mutation carriers.

Moran EE, Wang C, Katz M, Ozelius L, Schwartz A, Pavlovic J, Ortega RA, Lipton RB, Zimmerman ME, Saunders-Pullman R.

Neurobiol Aging. 2017 Oct;58:239.e1-239.e7. doi: 10.1016/j.neurobiolaging.2017.06.010. Epub 2017 Jun 24.

19.

Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program.

Gwinn K, David KK, Swanson-Fischer C, Albin R, Hillaire-Clarke CS, Sieber BA, Lungu C, Bowman FD, Alcalay RN, Babcock D, Dawson TM, Dewey RB Jr, Foroud T, German D, Huang X, Petyuk V, Potashkin JA, Saunders-Pullman R, Sutherland M, Walt DR, West AB, Zhang J, Chen-Plotkin A, Scherzer CR, Vaillancourt DE, Rosenthal LS.

Biomark Med. 2017 May;11(6):451-473. doi: 10.2217/bmm-2016-0370. Epub 2017 Jun 23.

20.

Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.

Lee AJ, Wang Y, Alcalay RN, Mejia-Santana H, Saunders-Pullman R, Bressman S, Corvol JC, Brice A, Lesage S, Mangone G, Tolosa E, Pont-Sunyer C, Vilas D, Schüle B, Kausar F, Foroud T, Berg D, Brockmann K, Goldwurm S, Siri C, Asselta R, Ruiz-Martinez J, Mondragón E, Marras C, Ghate T, Giladi N, Mirelman A, Marder K; Michael J. Fox LRRK2 Cohort Consortium.

Mov Disord. 2017 Oct;32(10):1432-1438. doi: 10.1002/mds.27059. Epub 2017 Jun 22.

21.

Complex and Dynamic Chromosomal Rearrangements in a Family With Seemingly Non-Mendelian Inheritance of Dopa-Responsive Dystonia.

Lohmann K, Redin C, Tönnies H, Bressman SB, Subero JIM, Wiegers K, Hinrichs F, Hellenbroich Y, Rakovic A, Raymond D, Ozelius LJ, Schwinger E, Siebert R, Talkowski ME, Saunders-Pullman R, Klein C.

JAMA Neurol. 2017 Jul 1;74(7):806-812. doi: 10.1001/jamaneurol.2017.0666.

22.

Finger extension weakness and downbeat nystagmus motor neuron disease syndrome: A novel motor neuron disorder?

Delva A, Thakore N, Pioro EP, Poesen K, Saunders-Pullman R, Meijer IA, Rucker JC, Kissel JT, Van Damme P.

Muscle Nerve. 2017 Dec;56(6):1164-1168. doi: 10.1002/mus.25669. Epub 2017 May 15.

23.

The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies.

Pont-Sunyer C, Tolosa E, Caspell-Garcia C, Coffey C, Alcalay RN, Chan P, Duda JE, Facheris M, Fernández-Santiago R, Marek K, Lomeña F, Marras C, Mondragon E, Saunders-Pullman R, Waro B; LRRK2 Cohort Consortium.

Mov Disord. 2017 May;32(5):726-738. doi: 10.1002/mds.26964. Epub 2017 Mar 28.

PMID:
28370517
24.

Functional Genomic Analyses of Mendelian and Sporadic Disease Identify Impaired eIF2α Signaling as a Generalizable Mechanism for Dystonia.

Rittiner JE, Caffall ZF, Hernández-Martinez R, Sanderson SM, Pearson JL, Tsukayama KK, Liu AY, Xiao C, Tracy S, Shipman MK, Hickey P, Johnson J, Scott B, Stacy M, Saunders-Pullman R, Bressman S, Simonyan K, Sharma N, Ozelius LJ, Cirulli ET, Calakos N.

Neuron. 2016 Dec 21;92(6):1238-1251. doi: 10.1016/j.neuron.2016.11.012. Epub 2016 Dec 8.

25.

Neuropsychiatric characteristics of GBA-associated Parkinson disease.

Swan M, Doan N, Ortega RA, Barrett M, Nichols W, Ozelius L, Soto-Valencia J, Boschung S, Deik A, Sarva H, Cabassa J, Johannes B, Raymond D, Marder K, Giladi N, Miravite J, Severt W, Sachdev R, Shanker V, Bressman S, Saunders-Pullman R.

J Neurol Sci. 2016 Nov 15;370:63-69. doi: 10.1016/j.jns.2016.08.059. Epub 2016 Aug 30.

26.

Digitized Spiral Drawing: A Possible Biomarker for Early Parkinson's Disease.

San Luciano M, Wang C, Ortega RA, Yu Q, Boschung S, Soto-Valencia J, Bressman SB, Lipton RB, Pullman S, Saunders-Pullman R.

PLoS One. 2016 Oct 12;11(10):e0162799. doi: 10.1371/journal.pone.0162799. eCollection 2016.

27.

Association Between Progranulin and Gaucher Disease.

Jian J, Zhao S, Tian QY, Liu H, Zhao Y, Chen WC, Grunig G, Torres PA, Wang BC, Zeng B, Pastores G, Tang W, Sun Y, Grabowski GA, Kong MX, Wang G, Chen Y, Liang F, Overkleeft HS, Saunders-Pullman R, Chan GL, Liu CJ.

EBioMedicine. 2016 Sep;11:127-137. doi: 10.1016/j.ebiom.2016.08.004. Epub 2016 Aug 4.

28.

Arm swing as a potential new prodromal marker of Parkinson's disease.

Mirelman A, Bernad-Elazari H, Thaler A, Giladi-Yacobi E, Gurevich T, Gana-Weisz M, Saunders-Pullman R, Raymond D, Doan N, Bressman SB, Marder KS, Alcalay RN, Rao AK, Berg D, Brockmann K, Aasly J, Waro BJ, Tolosa E, Vilas D, Pont-Sunyer C, Orr-Urtreger A, Hausdorff JM, Giladi N.

Mov Disord. 2016 Oct;31(10):1527-1534. doi: 10.1002/mds.26720.

29.

Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease.

Marras C, Alcalay RN, Caspell-Garcia C, Coffey C, Chan P, Duda JE, Facheris MF, Fernández-Santiago R, Ruíz-Martínez J, Mestre T, Saunders-Pullman R, Pont-Sunyer C, Tolosa E, Waro B; LRRK2 Cohort Consortium.

Mov Disord. 2016 Aug;31(8):1192-202. doi: 10.1002/mds.26614. Epub 2016 Apr 19.

PMID:
27091104
30.

Glucocerebrosidase enzyme activity in GBA mutation Parkinson's disease.

Ortega RA, Torres PA, Swan M, Nichols W, Boschung S, Raymond D, Barrett MJ, Johannes BA, Severt L, Shanker V, Hunt AL, Bressman S, Pastores GM, Saunders-Pullman R.

J Clin Neurosci. 2016 Jun;28:185-6. doi: 10.1016/j.jocn.2015.12.004. Epub 2016 Feb 5.

31.

Psychiatric disorders, myoclonus dystonia and SGCE: an international study.

Peall KJ, Dijk JM, Saunders-Pullman R, Dreissen YE, van Loon I, Cath D, Kurian MA, Owen MJ, Foncke EM, Morris HR, Gasser T, Bressman S, Asmus F, Tijssen MA.

Ann Clin Transl Neurol. 2015 Nov 20;3(1):4-11. doi: 10.1002/acn3.263. eCollection 2016 Jan.

32.

Secondary orthostatic tremor in the setting of cerebellar degeneration.

Sarva H, Severt WL, Jacoby N, Pullman SL, Saunders-Pullman R.

J Clin Neurosci. 2016 May;27:173-5. doi: 10.1016/j.jocn.2015.10.027. Epub 2016 Jan 4.

PMID:
26765757
33.

GBA mutations are associated with Rapid Eye Movement Sleep Behavior Disorder.

Gan-Or Z, Mirelman A, Postuma RB, Arnulf I, Bar-Shira A, Dauvilliers Y, Desautels A, Gagnon JF, Leblond CS, Frauscher B, Alcalay RN, Saunders-Pullman R, Bressman SB, Marder K, Monaca C, Högl B, Orr-Urtreger A, Dion PA, Montplaisir JY, Giladi N, Rouleau GA.

Ann Clin Transl Neurol. 2015 Sep;2(9):941-5. doi: 10.1002/acn3.228. Epub 2015 Jul 31.

34.

REM sleep behavior disorder, as assessed by questionnaire, in G2019S LRRK2 mutation PD and carriers.

Saunders-Pullman R, Alcalay RN, Mirelman A, Wang C, Luciano MS, Ortega RA, Glickman A, Raymond D, Mejia-Santana H, Doan N, Johannes B, Yasinovsky K, Ozelius L, Clark L, Orr-Utreger A, Marder K, Giladi N, Bressman SB; AJ LRRK2 Consortium.

Mov Disord. 2015 Nov;30(13):1834-9. doi: 10.1002/mds.26413. Epub 2015 Sep 14.

35.

Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium.

Marder K, Wang Y, Alcalay RN, Mejia-Santana H, Tang MX, Lee A, Raymond D, Mirelman A, Saunders-Pullman R, Clark L, Ozelius L, Orr-Urtreger A, Giladi N, Bressman S; LRRK2 Ashkenazi Jewish Consortium.

Neurology. 2015 Jul 7;85(1):89-95. doi: 10.1212/WNL.0000000000001708. Epub 2015 Jun 10.

36.

Disclosure of research results in genetic studies of Parkinson's disease caused by LRRK2 mutations.

Pont-Sunyer C, Bressman S, Raymond D, Glickman A, Tolosa E, Saunders-Pullman R.

Mov Disord. 2015 Jun;30(7):904-8. doi: 10.1002/mds.26250. Epub 2015 May 7.

37.

Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene.

Mirelman A, Alcalay RN, Saunders-Pullman R, Yasinovsky K, Thaler A, Gurevich T, Mejia-Santana H, Raymond D, Gana-Weisz M, Bar-Shira A, Ozelius L, Clark L, Orr-Urtreger A, Bressman S, Marder K, Giladi N; LRRK2 AJ consortium.

Mov Disord. 2015 Jun;30(7):981-6. doi: 10.1002/mds.26213. Epub 2015 Mar 21.

38.

Low-variance RNAs identify Parkinson's disease molecular signature in blood.

Chikina MD, Gerald CP, Li X, Ge Y, Pincas H, Nair VD, Wong AK, Krishnan A, Troyanskaya OG, Raymond D, Saunders-Pullman R, Bressman SB, Yue Z, Sealfon SC.

Mov Disord. 2015 May;30(6):813-21. doi: 10.1002/mds.26205. Epub 2015 Mar 18.

39.

Olfactory identification in LRRK2 G2019S mutation carriers: a relevant marker?

Saunders-Pullman R, Mirelman A, Wang C, Alcalay RN, San Luciano M, Ortega R, Raymond D, Mejia-Santana H, Ozelius L, Clark L, Orr-Utreger A, Marder K, Giladi N, Bressman SB.

Ann Clin Transl Neurol. 2014 Sep;1(9):670-8. doi: 10.1002/acn3.95. Epub 2014 Sep 30.

40.

Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease.

Alcalay RN, Mejia-Santana H, Mirelman A, Saunders-Pullman R, Raymond D, Palmese C, Caccappolo E, Ozelius L, Orr-Urtreger A, Clark L, Giladi N, Bressman S, Marder K; LRRK2 Ashkenazi Jewish Consortium.

Parkinsonism Relat Disord. 2015 Feb;21(2):106-10. doi: 10.1016/j.parkreldis.2014.09.033. Epub 2014 Nov 20.

41.

Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.

Agalliu I, San Luciano M, Mirelman A, Giladi N, Waro B, Aasly J, Inzelberg R, Hassin-Baer S, Friedman E, Ruiz-Martinez J, Marti-Masso JF, Orr-Urtreger A, Bressman S, Saunders-Pullman R.

JAMA Neurol. 2015 Jan;72(1):58-65. doi: 10.1001/jamaneurol.2014.1973.

42.

Compound heterozygous PNPLA6 mutations cause Boucher-Neuhäuser syndrome with late-onset ataxia.

Deik A, Johannes B, Rucker JC, Sánchez E, Brodie SE, Deegan E, Landy K, Kajiwara Y, Scelsa S, Saunders-Pullman R, Paisán-Ruiz C.

J Neurol. 2014 Dec;261(12):2411-23. doi: 10.1007/s00415-014-7516-3. Epub 2014 Sep 30.

43.

Interest in genetic testing in Ashkenazi Jewish Parkinson's disease patients and their unaffected relatives.

Gupte M, Alcalay RN, Mejia-Santana H, Raymond D, Saunders-Pullman R, Roos E, Orbe-Reily M, Tang MX, Mirelman A, Ozelius L, Orr-Urtreger A, Clark L, Giladi N, Bressman S, Marder K.

J Genet Couns. 2015 Apr;24(2):238-46. doi: 10.1007/s10897-014-9756-x. Epub 2014 Aug 17.

44.

Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants.

Alcalay RN, Aasly J, Berg D, Bressman S, Brice A, Brockmann K, Chan P, Clark L, Cormier F, Corvol JC, Durr A, Facheris M, Farrer M, Foroud TM, Gasser T, Giladi N, Halter C, Lang A, Langston JW, Marras C, Marti-Masso JF, Ruiz Martinez J, Mejia-Santana H, Mirelman A, Pont-Sunyer C, Orr-Urtreger A, Raymond D, Saunders-Pullman R, Schüle B, Tanner C, Tolosa E, Urkowitz A, Vilas D, Wise A, Marder K.

Genet Med. 2014 Aug;16(8):644-5. doi: 10.1038/gim.2014.55. No abstract available.

45.

A-TWinnipeg: Pathogenesis of rare ATM missense mutation c.6200C>A with decreased protein expression and downstream signaling, early-onset dystonia, cancer, and life-threatening radiotoxicity.

Nakamura K, Fike F, Haghayegh S, Saunders-Pullman R, Dawson AJ, Dörk T, Gatti RA.

Mol Genet Genomic Med. 2014 Jul;2(4):332-40. doi: 10.1002/mgg3.72. Epub 2014 Mar 13.

46.

Cognitive and Antipsychotic Medication Use in Monoallelic GBA-Related Parkinson Disease.

Barrett MJ, Shanker VL, Severt WL, Raymond D, Gross SJ, Schreiber-Agus N, Kornreich R, Ozelius LJ, Bressman SB, Saunders-Pullman R.

JIMD Rep. 2014;16:31-8. doi: 10.1007/8904_2014_315. Epub 2014 May 22.

47.

Genome-wide mapping of IBD segments in an Ashkenazi PD cohort identifies associated haplotypes.

Vacic V, Ozelius LJ, Clark LN, Bar-Shira A, Gana-Weisz M, Gurevich T, Gusev A, Kedmi M, Kenny EE, Liu X, Mejia-Santana H, Mirelman A, Raymond D, Saunders-Pullman R, Desnick RJ, Atzmon G, Burns ER, Ostrer H, Hakonarson H, Bergman A, Barzilai N, Darvasi A, Peter I, Guha S, Lencz T, Giladi N, Marder K, Pe'er I, Bressman SB, Orr-Urtreger A.

Hum Mol Genet. 2014 Sep 1;23(17):4693-702. doi: 10.1093/hmg/ddu158. Epub 2014 May 19.

48.

The complexities of hormonal influences and risk of Parkinson's disease.

Marras C, Saunders-Pullman R.

Mov Disord. 2014 Jun;29(7):845-8. doi: 10.1002/mds.25891. Epub 2014 Apr 30. No abstract available.

49.

Heterogeneity in primary dystonia: lessons from THAP1, GNAL, and TOR1A in Amish-Mennonites.

Saunders-Pullman R, Fuchs T, San Luciano M, Raymond D, Brashear A, Ortega R, Deik A, Ozelius LJ, Bressman SB.

Mov Disord. 2014 May;29(6):812-8. doi: 10.1002/mds.25818. Epub 2014 Feb 5.

50.

Atypical presentation of late-onset Tay-Sachs disease.

Deik A, Saunders-Pullman R.

Muscle Nerve. 2014 May;49(5):768-71. doi: 10.1002/mus.24146. Epub 2014 Feb 24.

Supplemental Content

Loading ...
Support Center